Drug Trial Radar · NCT03439085
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
Last checked: Nov 19, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
41
Actual
Start
Nov 14, 2018
Primary completion
Sep 20, 2022
Study completion Sep 20, 2022
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab may work better in treating patients with human papillomavirus associated cancers.
Conditions
- Human Papillomavirus-16 Positive
- Human Papillomavirus-18 Positive
- Metastatic Malignant Neoplasm
- Recurrent Anal Canal Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Penile Carcinoma
- Recurrent Vaginal Carcinoma
- Recurrent Vulvar Carcinoma
- Refractory Malignant Neoplasm
- Stage IV Anal Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Vaginal Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Vaginal Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457Biological
Given IM and via electroporation
DurvalumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.